Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beike Biotech Acquires Altor's Cancer Drug in $200 Million Deal

publication date: Sep 10, 2014
Shenzhen Beike Biotechnology acquired China rights to a novel cancer immunotherapy developed by Altor BioScience of Florida. ALT-803 is Altor’s proprietary Interleukin-15 (IL-15) based superagonist complex that is currently in four US Phase I/II clinical trials for various indications. Beike made an upfront payment of $4 million and invested another $5 million in Altor. Beike also agreed to a package of over $200 million in development and sales milestones and will pay a tiered double-digit royalty on sales. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital